Carna Biosciences, Inc.
4572.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.80 | -0.26 | 0.17 | -0.18 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -7.20 | -10.21 | -8.24 | -6.28 |
| Quality | ||||
| ROIC | -35.97% | -37.80% | -24.36% | -19.33% |
| Gross Margin | 67.17% | 68.62% | 69.63% | 68.21% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -18.41% | -18.26% | -17.28% | -22.85% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.90 | 1.91 | 3.08 | 3.52 |
| Interest Coverage | -14.72 | -1,277.14 | -1,081.05 | -892.64 |
| Efficiency | ||||
| Inventory Turnover | 0.31 | 0.21 | 0.27 | 0.31 |
| Cash Conversion Cycle | 336.21 | 494.67 | 384.76 | 341.64 |